您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > C-Type Natriuretic Peptide(CNP)(1-22),human TFA
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
C-Type Natriuretic Peptide(CNP)(1-22),human TFA
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
规格:98%
分子量:2311.62
包装与价格:
包装价格(元)
500ug电议
1mg电议
5mg电议

产品介绍
C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP).
货号:ajcx35698
CAS:1966153-17-2
分子式:C95H158F3N27O30S3
分子量:2311.62
溶解度:H2O : 2 mg/mL (0.87 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP). C-Type Natriuretic Peptide (CNP) is a selective agonist of natriuretic peptide receptors NPR-B and C (Kds = 7, and 10.8 pM)[1].

C-Type Natriuretic Peptide (CNP) (1-22), significantly promoted longitudinal bone growth in an organ culture experiment using tibiae from fetal mice[2]. C-Type Natriuretic Peptide (CNP) (1-22) in vivo administration might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic and antihypertrophic action[3]. NPR-B-mediated cGMP production after CNP administration specifically acted on the pylorus, colon, and rectum and contributed to gastric emptying[1].

参考文献:
[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.
[2]. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11 695-11 700
[3]. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. 2005.J Am Coll Cardiol 45:608-616

Protocol:

Animal experiment [2]:

Animal models

Four-week-old female ddY mice

Preparation Method

Mice were separated into four groups: the untreated (baseline) group, the 2 mg/kg C-Type Natriuretic Peptide (CNP) group, the 1 mg/kg C-Type Natriuretic Peptide (CNP) group, and the vehicle (normal saline) group. C-Type Natriuretic Peptide (CNP) and vehicle were administered intravenously.

Dosage form

Intravenously injection, 1 or 2 mg/kg

Applications

In the pylorus and rectum, after 2 mg/kg C-Type Natriuretic Peptide (CNP) was administered, cGMP production was remarkably increased as early as 1 minute compared with that after 1 mg/kg C-Type Natriuretic Peptide (CNP) was administered

参考文献:

[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.